JCEM: Oral bisphosphonates reduce cardiovascular events in patients with abnormal bone density.

!---- The cardiovascular (CV) safety of oral bisphosphonates (BIs) is not yet clear., an authoritative journal of endocrine and metabolic diseases recently published a study in Journal of Clinical Endocrinology and Metabolism that aims to clarify the risk of CV events in oral BP users compared to matching controls.the study is a cohort study based on hospital data from the Danish National Prescription Registry.participants were individuals who underwent bone density (BMD) tests for the age of 45.exposure factor is oral BP.the outcome of the study was hospitalization for any CV event.secondary study outcome seiscasts for specific CV events.negative (anal hernia surgery and toenail inward growth) and positive (vulnerability fractures) were assessed for systemic bias in contrast.fit the Cox Scale Risk Model to estimate the risk ratio (HR) (95% confidence interval).the study had 2,565 oBP users (82.6 per cent female) and 4,568 female controls (82.3 per cent female) who matched their preference scores.alenphosphate accounts for 96% of BP's prescriptions. a total of 406 (15.8%) CV events occurred inoral BP users (incidence rate of 73.48 (66.67 to 80.98);other adjustments to the BMD do not weaken the estimate (HR is 0.67 (0.58 to 0.78).)observed similar results for secondary outcomes in terms of reduced risk of atrial fibrillation, stroke, heart failure and aneurysm.positive and negative control outcome analysis determined the smallest residual mix., the risk of CV events for oral BP users was reduced by 33%.this observational real-world study provides more and more evidence for oral BP for cardiac protection, further evaluation is necessary in randomized trials. .